Jianqing Li

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6437088/publications.pdf

Version: 2024-02-01

		858243	759306
29	523	12	22
papers	citations	h-index	g-index

32	32	32	801
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy. Journal of Medicinal Chemistry, 2022, 65, 1770-1785.	2.9	42
2	Synthesis Optimization, Scale-Up, and Catalyst Screening Efforts toward the MGAT2 Clinical Candidate, BMS-963272. Organic Process Research and Development, 2022, 26, 1327-1335.	1.3	4
3	Discovery of Two Novel Antiplatelet Clinical Candidates (BMS-986120 and BMS-986141) That Antagonize Protease-Activated Receptor 4. Journal of Medicinal Chemistry, 2022, 65, 8843-8854.	2.9	14
4	Discovery and Preclinical Pharmacology of an Oral Bromodomain and Extra-Terminal (BET) Inhibitor Using Scaffold-Hopping and Structure-Guided Drug Design. Journal of Medicinal Chemistry, 2021, 64, 14247-14265.	2.9	23
5	Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2. Journal of Medicinal Chemistry, 2021, 64, 677-694.	2.9	41
6	Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA₁) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases. Journal of Medicinal Chemistry, 2021, 64, 15549-15581.	2.9	21
7	Intramolecular [2+2] Cycloaddition of Nâ€Allylcinnamamines and Nâ€Allylcinnamamides by Visibleâ€Light Photocatalysis. European Journal of Organic Chemistry, 2020, 2020, 41-46.	1.2	16
8	Synthesis of 1-(tert-Butyl) 4-Methyl (1R,2S,4R)-2-Methylcyclohexane-1,4-dicarboxylate from Hagemannâ€™s tert-Butyl Ester for an Improved Synthesis of BMS-986251. Journal of Organic Chemistry, 2020, 85, 10988-10993.	1.7	7
9	Synthesis of Differentially Protected Azatryptophan Analogs via Pd₂(dba)₃/XPhos Catalyzed Negishi Coupling of N-Ts Azaindole Halides with Zinc Derivative from Fmoc-Protected tert-Butyl (R)-2-Amino-3-iodopropanoate. Journal of Organic Chemistry, 2020, 85, 11519-11530.	1.7	5
10	Multigram Synthesis of BMS-929075, an Allosteric, Palm Site Inhibitor of HCV NS5B Replicase, Involving the Synthesis of a Highly Functionalized Benzofuran through a Telescoped Process. Organic Process Research and Development, 2020, 24, 1157-1163.	1.3	10
11	A mild and readily scalable procedure for the N-1-difluoromethylation of ethyl 6-((tert-butyldiphenylsilyl)oxy)-1H-indazole-3-carboxylate and its applications to the N-difluoromethylation of indazole, benzotriazole, imidazole, indole and pyrazole derivatives. Journal of Fluorine Chemistry, 2020, 234, 109514.	0.9	2
12	A Practical Synthesis of the TGFÎ²RI Inhibitor N-(4-(3-(6-(Difluoromethyl)pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide via One-Pot Sequential Sonogashira and Cacchi Reactions Catalyzed by Pd(OAc)₂/BINAP. Organic Process Research and Development, 2020, 24, 454-458.	1.3	4
13	Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Brutonâ€™s Tyrosine Kinase (BTK). Journal of Medicinal Chemistry, 2019, 62, 3228-3250.	2.9	78
14	Identification and Preclinical Evaluation of the Bicyclic Pyrimidine Î³-Secretase Modulator BMS-932481. ACS Medicinal Chemistry Letters, 2019, 10, 312-317.	1.3	13
15	BMS-986163, a Negative Allosteric Modulator of GluN2B with Potential Utility in Major Depressive Disorder. ACS Medicinal Chemistry Letters, 2018, 9, 472-477.	1.3	13
16	Evolution of a Scale-Up Synthesis to a Potent GluN2B Inhibitor and Its Prodrug. Organic Process Research and Development, 2018, 22, 846-855.	1.3	5
17	Abstract 5789: Discovery of clinical candidate BMS-986158, an oral BET inhibitor, for the treatment of cancer. Cancer Research, 2018, 78, 5789-5789.	0.4	13
18	Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3â€²-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11Î²-Hydroxysteroid Dehydrogenase Type 1 Inhibitor. Journal of Medicinal Chemistry, 2017, 60, 4932-4948.	2.9	10

#	Article	IF	Citations
19	Enantioselective synthesis of BMS-911278: a triple reuptake inhibitor. Tetrahedron: Asymmetry, 2017, 28, 196-202.	1.8	4
20	Preclinical Characterization of (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), a Novel, Intravenous, Glutamate N-Methyl-d-Aspartate 2B Receptor Negative Allosteric Modulator with Potential in Major Depressive Disorder. Journal of Pharmacology and Experimental Therapeutics, 2017, 363, 377-393.	1.3	15
21	Development of the Large-Scale Synthesis of Tetrahydropyran Glycine, a Precursor to the HCV NS5A Inhibitor BMS-986097. Journal of Organic Chemistry, 2017, 82, 10376-10387.	1.7	8
22	Regioselective Synthesis of Substituted 4-Alkylamino and 4-Arylaminophthalazin-1(2H)-ones. Journal of Organic Chemistry, 2016, 81, 1520-1526.	1.7	10
23	An efficient one-pot synthesis of substituted 2-aminobenzo-1-thiophene-3-carbonitriles. Tetrahedron Letters, 2015, 56, 3766-3768.	0.7	6
24	Triphenylethanamine Derivatives as Cholesteryl Ester Transfer Protein Inhibitors: Discovery of N-[(1R)-1-(3-Cyclopropoxy-4-fluorophenyl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(trifluo (BMS-795311). Journal of Medicinal Chemistry, 2015, 58, 9010-9026.	2.9	11
25	AlMe₃-Promoted Formation of Amides from Acids and Amines. Organic Letters, 2012, 14, 214-217.	2.4	43
26	An Efficient, Direct Bis-ortho-chlorination of 4-(Difluoromethoxy)aniline and Its Application to the Synthesis of BMS-665053, a Potent and Selective Pyrazinone-Containing Corticotropin-Releasing Factor-1 Receptor Antagonist. Organic Process Research and Development, 2012, 16, 156-159.	1.3	9
27	Preparation of Monofluorophenols via the Reaction of Difluorobenzene Derivatives with Potassium Trimethylsilanoate. Synlett, 2009, 2009, 633-637.	1.0	5
28	Discovery of a 2,4-Disubstituted Pyrrolo[1,2-f][1,2,4]triazine Inhibitor (BMS-754807) of Insulin-like Growth Factor Receptor (IGF-1R) Kinase in Clinical Development. Journal of Medicinal Chemistry, 2009, 52, 7360-7363.	2.9	87
29	Development of a Rapid Scale-Up Synthesis of (S)-N-(8-((2-Amino-2,4-dimethylpentyl)oxy)-5H-chromeno[3,4-c]pyridin-2-yl)acetamide, a Potent Adaptor-Associated Kinase 1 Inhibitor. Organic Process Research and Development, 0, , .	1.3	4